EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Functional Characterization of a Novel MYBPC3 Splice-Altering Variant Identified in a Chinese Patient with Hypertrophic Cardiomyopathy

Hangyu Liu, Juan Hua, Qinmei Xiong, Liang Xiong, Qi Chen

Journal of Cardiovascular Development and Disease · 2026-11-10 · 13 (11) · 582

DOI: 10.3390/jcdd13110582 ↗
AbstractBibliografische Angaben

Abstract

Background: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous myocardial disorder in which variants in MYBPC3 represent a major genetic cause, although the functional significance of newly identified splice-region variants often remains uncertain. Methods: We investigated a previously unreported heterozygous MYBPC3 variant, NM_000256.3: c.2414-6_2421del, identified by whole-exome sequencing in a Chinese male patient with HCM and cardiac dysfunction. Adenoviral vectors expressing wild-type (Ad-WT) or mutant (Ad-MUT) MYBPC3 were used to establish cardiomyocyte models. Results: Compared with Ad-WT cells, Ad-MUT cells showed increased ANP and BNP expression, enhanced ERK phosphorylation, and cytoskeletal alterations assessed by phalloidin staining, indicating a hypertrophic cellular response. Three region-specific RT-qPCR assays demonstrated reduced MYBPC3 transcript abundance in Ad-MUT cells, with a greater reduction in the exon 25–26-spanning amplicon, suggesting altered RNA processing involving the variant-adjacent region. Cycloheximide treatment increased the abundance of mutant-associated transcripts, supporting their degradation through nonsense-mediated mRNA decay. Conclusions: MYBPC3 c.2414-6_2421del disrupts transcript processing and promotes nonsense-mediated mRNA decay (NMD)-associated transcript depletion, accompanied by cardiomyocyte hypertrophic remodeling. These findings provide functional evidence relevant to the interpretation of this previously unreported variant in HCM.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →